Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
Source: Targeted Oncology, May 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
DISCUSSION QUESTIONS
- How do you balance efficacy, safety, patient preferences, goals of therapy, and quality of life when recommending a first-line regimen in melanoma??
- How does the availability of a novel immunotherapy target (anti-LAG3) change the landscape and decision-making process?
EVAN J. LIPSON, MD: Could you talk for about patient preference and how that plays into the recommendation you make?